REGiMMUNE Corporation is a biotechnology company focused on the discovery, development, and potential commercialization of immune-regulatory therapeutics to treat life-threatening diseases and debilitating disorders, including allergies, autoimmune and inflammatory disease. REGiMMUNE applies its reVax (reverse vaccination) technology and product development and clinical experience to generate, support and potentially commercialize a broad range of products for itself and its partners.

Our business strategy is to develop novel and proprietary products focused on therapeutic areas that can be addressed with immune-regulating technology. We expedite programs by actively using outside resources and partnering with biotechnology and pharmaceutical companies to leverage technology assets. Our growth is driven by our flexible and precision management based on clear-sighted vision.
　
　
[Company Name]
REGiMMUNE Corporation
　
[Founded]
March 3, 2006
　
[Headquarters]
1-7-8 Kaigan
Tokyo Industrial Trade Center 607 (6th Floor)
Minato-ku Tokyo 105-0022 JAPAN
+81-3-6809-2199
　
[US Office]
320 Logue Ave.,
Mountain View, CA 94043, USA
+1.650.938.6530
　
[Company Representative]
Haru Morita
　
[Businesses]
Research and Development of Pharmaceutical Products
　
[Investors]
NIF SMBC Ventures Co., Ltd.
Japan Asia Investment Co., Ltd.
Yasuda Enterprise Development Co., Ltd.
CSK VENTURE CAPITAL CO., LTD.
JAFCO Co., Ltd.
Orix Capital Corporation, Ltd.
New Business Investment Co., Ltd.
Nikko Antfactory K.K.
WERU Investment Co. Ltd.
Tokyo Small and Medium Business Investment & Consultation Co., Ltd.
GH Holdings K.K.
Sansei Capital Investment Co.Ltd.
Resona Capital Co.,Ltd.
Fund Creation Co., Ltd.
Mitsubishi UFJ Capital Co., Ltd.
Tokyo Tomin Bank Investment Co. Ltd.
Schiemann and Associates Co. Ltd.